LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Recursion Pharmaceuticals Inc

Slēgts

SektorsVeselības aprūpe

5.48 20.44

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

5.3

Max

5.48

Galvenie mērījumi

By Trading Economics

Ienākumi

-24M

-202M

Pārdošana

10M

15M

EPS

-0.5

Peļņas marža

-1,373.259

Darbinieki

800

EBITDA

-26M

-191M

Rekomendācijas

By TipRanks

Rekomendācijas

Neitrāls

Prognoze 12 mēnešiem

+47.7% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 7. aug.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-570M

1.7B

Iepriekšējā atvēršanas cena

-14.96

Iepriekšējā slēgšanas cena

5.48

Ziņu noskaņojums

By Acuity

50%

50%

166 / 380 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bearish Evidence

Recursion Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 6. jūn. 14:31 UTC

Peļņas

New York State Retirement Fund Posts 5.84% Annual Investment Return

2025. g. 6. jūn. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 6. jūn. 20:50 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2025. g. 6. jūn. 20:33 UTC

Peļņas

These Stocks Moved the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

2025. g. 6. jūn. 19:36 UTC

Tirgus saruna

Oil Futures Post Solid Weekly Gains -- Market Talk

2025. g. 6. jūn. 19:28 UTC

Tirgus saruna

U.S. Natural Gas Futures Rise on Demand Expectations -- Market Talk

2025. g. 6. jūn. 18:46 UTC

Tirgus saruna

Gold Faced With Tariff Uncertainty Offset by ETF Withdrawals -- Market Talk

2025. g. 6. jūn. 18:02 UTC

Tirgus saruna

U.S. Oil Rig Count Continues to Decline -- Market Talk

2025. g. 6. jūn. 16:35 UTC

Peļņas

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

2025. g. 6. jūn. 16:34 UTC

Peļņas

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

2025. g. 6. jūn. 16:21 UTC

Tirgus saruna

Canadian Unemployment Set to Continue Feel Trade War Pressures -- Market Talk

2025. g. 6. jūn. 16:20 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2025. g. 6. jūn. 16:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 6. jūn. 16:20 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2025. g. 6. jūn. 16:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2025. g. 6. jūn. 16:07 UTC

Tirgus saruna

Market Talk Roundup: Latest on U.S. Politics

2025. g. 6. jūn. 16:07 UTC

Tirgus saruna

Base Metal Prices Slide But Copper Set to End Week Higher -- Market Talk

2025. g. 6. jūn. 15:53 UTC

Tirgus saruna

Mexican Inflation Seen Rising in May -- Market Talk

2025. g. 6. jūn. 15:36 UTC

Tirgus saruna

Dollar's Boost From U.S. Jobs Data Could Be Limited -- Market Talk

2025. g. 6. jūn. 15:36 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 6. jūn. 15:33 UTC

Tirgus saruna

Gold Futures Slide After Jobs Data Surprises to Upside -- Market Talk

2025. g. 6. jūn. 15:16 UTC

Tirgus saruna

Tesla Showing Signs of Weakness in Key Regions -- Market Talk

2025. g. 6. jūn. 15:05 UTC

Tirgus saruna

Silver at its Highest In Nearly 15 Years -- Market Talk

2025. g. 6. jūn. 14:35 UTC

Tirgus saruna

Weakening Canadian Job Market Seen Keeping BoC in Easing Mode -- Market Talk

2025. g. 6. jūn. 14:28 UTC

Tirgus saruna

Bitcoin Rises After Above-Forecast U.S. Jobs Data -- Market Talk

2025. g. 6. jūn. 14:28 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 6. jūn. 14:28 UTC

Tirgus saruna

Canada's Job Market Weakens But Not Seen Collapsing -- Market Talk

2025. g. 6. jūn. 14:15 UTC

Tirgus saruna

Oil Rises on U.S.-China Talks Optimism -- Market Talk

2025. g. 6. jūn. 14:12 UTC

Peļņas

Palantir and Super Micro Computer Stocks Rise as Broadcom Posts Strong AI Revenue -- Barrons.com

2025. g. 6. jūn. 14:09 UTC

Peļņas

Broadcom, the $1 Trillion Stock You Shouldn't Ignore, Makes AI Investment Case -- Barrons.com

Salīdzinājums

Cenas izmaiņa

Recursion Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

47.7% augšup

Prognoze 12 mēnešiem

Vidējais 6.75 USD  47.7%

Augstākais 8 USD

Zemākais 3 USD

Pamatojoties uz 5 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Recursion Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Neitrāls

5 ratings

1

Pirkt

4

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

4.15 / 4.75Atbalsts un pretestība

Īstermiņā

Very Strong Bearish Evidence

Vidējā termiņā

Bearish Evidence

Ilgtermiņā

Bearish Evidence

Noskaņojums

By Acuity

166 / 380 Rangs Veselības aprūpe

Ziņu noskaņojums

Neutral

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.